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Abstract
Background: A limiting antigen avidity enzyme immunoassay (HIV-1 LAg-Avidity assay) was recently developed for cross-
sectional HIV incidence estimation. We evaluated the performance of the LAg-Avidity assay alone and in multi-assay
algorithms (MAAs) that included other biomarkers.
Methods and Findings: Performance of testing algorithms was evaluated using 2,282 samples from individuals in the
United States collected 1 month to .8 years after HIV seroconversion. The capacity of selected testing algorithms to
accurately estimate incidence was evaluated in three longitudinal cohorts. When used in a single-assay format, the LAg-
Avidity assay classified some individuals infected .5 years as assay positive and failed to provide reliable incidence
estimates in cohorts that included individuals with long-term infections. We evaluated .500,000 testing algorithms, that
included the LAg-Avidity assay alone and MAAs with other biomarkers (BED capture immunoassay [BED-CEIA], BioRad-
Avidity assay, HIV viral load, CD4 cell count), varying the assays and assay cutoffs. We identified an optimized 2-assay MAA
that included the LAg-Avidity and BioRad-Avidity assays, and an optimized 4-assay MAA that included those assays, as well
as HIV viral load and CD4 cell count. The two optimized MAAs classified all 845 samples from individuals infected .5 years
as MAA negative and estimated incidence within a year of sample collection. These two MAAs produced incidence
estimates that were consistent with those from longitudinal follow-up of cohorts. A comparison of the laboratory assay
costs of the MAAs was also performed, and we found that the costs associated with the optimal two assay MAA were
substantially less than with the four assay MAA.
Conclusions: The LAg-Avidity assay did not perform well in a single-assay format, regardless of the assay cutoff. MAAs that
include the LAg-Avidity and BioRad-Avidity assays, with or without viral load and CD4 cell count, provide accurate incidence
estimates.
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Introduction
HIV incidence measures the rate of new HIV infections in a
population [1]. Accurate incidence estimates are needed to
identify populations at increased risk of HIV acquisition, monitor
the HIV/AIDS epidemic, and evaluate interventions for HIV
prevention [2,3]. Cohort studies that identify HIV seroconverters
are expensive and time-consuming, and may not provide reliable
incidence estimates because of selection bias, changes in behavior
associated with study participation, and loss to follow-up [4].
Unfortunately, serologic assays developed for cross-sectional
incidence estimation often overestimate HIV incidence because
some long-term infections are classified as assay positive (incident)
[5–9]. Use of multi-assay algorithms (MAAs) to estimate incidence
in cross-sectional surveys is a promising alternative approach for
estimating HIV incidence [10,11]. We recently demonstrated that
accurate incidence estimates can be obtained using MAAs that
include the BED capture immunoassay (BED-CEIA) [12], the
BioRad-Avidity assay [13], and viral load, with or without a
second non-serologic biomarker (either CD4 cell count or HIV
diversity) [14–16].
The United States (US) Centers for Disease Control recently
developed a limiting antigen avidity enzyme immunoassay (LAg-
Avidity assay) for cross-sectional HIV incidence estimation
[17,18]. This assay measures the avidity of antibody binding to
low concentrations of a multi-subtype peptide derived from an
immunodominant region of gp41. This assay is commercially
available and has been promoted for HIV incidence estimation
[19,20]. However, data from other research groups supporting use
of this assay are limited [21], and a recent editorial called for a
thorough independent evaluation of the LAg-Avidity assay [22].
The kit manufacturer (SEDIA Biosciences, Portland, OR)
recommends excluding individuals with advanced HIV disease
(e.g., CD4 cell count ,200 cells/mm
3), elite controllers, and
individuals on antiretroviral therapy from incidence surveys [23].
However, no guidance is provided in the package insert on how to
combine data from the LAg-Avidity assay and other assays, or
what cutoffs should be used for other assays (e.g., HIV viral load).
The manufacturer recently recommended increasing the LAg-
Avidity assay cutoff from 1.0 to 1.5 normalized optical density
units (OD-n) and reducing the mean window period used for
incidence estimation from 141 to 130 days [24]; the mean window
period is the average time that an individual appears recently
infected using an assay or MAA.
In this report, we evaluated the performance of the LAg-Avidity
assay alone and in MAAs that included other serologic and non-
serologic biomarkers. We evaluated the probability that samples
were classified as assay positive or MAA positive over time (using
tabulated classification frequencies and fitted smoothed spline
curves). We also compared the mean window periods and shadows
of the different testing approaches, as well as the relative sample
sizes needed for incidence surveys, and relative costs. Finally, we
evaluated the ability of the different testing approaches to produce
incidence estimates in three cohorts with low, medium, and high
incidence that were consistent with those obtained by direct
longitudinal follow-up.
Methods
Ethics Statement
Written informed consent was obtained from study participants
and all studies were reviewed and approved by relevant
institutional review boards. Only stored samples from individuals
who consented to have their samples could be used for future
research were used in this investigation. No new samples were
obtained specifically for this study. The study for cross sectional
incidence testing on stored study samples was approved by the
institutional review board of the Johns Hopkins University. The
research was conducted according to the principles expressed in
the Declaration of Helsinki.
Samples used for analysis
The performance of the LAg-Avidity assay and MAAs that
include the LAg-Avidity assay was evaluated using 1,782 plasma
and serum samples from three cohort studies in the US (duration
of infection from 1 month to .8 years): the Multicenter AIDS
Cohort Study [25] (MACS, men who have sex with men [MSM],
564 samples, 3 to .8 years after seroconversion), the AIDS Linked
to the IntraVenous Experience cohort [26] (ALIVE, persons who
inject drugs, 410 samples, 2 to 6 years after seroconversion), and
the HIV Network for Prevention Trials 001/001.1 vaccine
preparedness cohort [27] (HIVNET 001, men and women with
different risk factors for HIV infection, 808 samples, 1 month to 4
years after seroconversion). Further assessments were performed
using 500 additional samples from the Johns Hopkins Hospital
Clinical Cohort [28] (JHHCC, varied risk factors, approximately
one half are persons who inject drugs, all .8 years after
seroconversion). Detailed descriptions of these sample sets are
provided in previous publications [14,29]. Two of the 1,782
samples did not have data from the LAg-Avidity assay; those
samples were not included in the initial search for optimal testing
algorithms (see below), but were included in some of the
subsequent analyses. Cross-sectional incidence estimates were
generated using additional samples obtained from the HIVNET
001 study (see above) [27], and two other cohort studies from the
US: the HIV Prevention Trials Network (HPTN) 061 study (a
study of black MSM in the US) [30] and the HPTN 064 study (a
study of women with increased HIV acquisition risk from high
poverty and HIV prevalence areas in the US) [31].
Laboratory methods
The LAg-Avidity assay (HIV-1 LAg-Avidity EIA, SEDIA
Biosciences Corporation, Portland, OR) was performed according
to the manufacturer’s instructions. The results are reported as
OD-n. Samples with an initial result ,2.0 OD-n were retested in
triplicate for confirmation and the median confirmation value was
used for analysis. Most of the data for the BED-CEIA, the BioRad-
Avidity assay, and HIV viral load were generated in previous
studies. The BED-CEIA (Calypte Biomedical Corporation, Lake
Oswego, OR) was performed according to the manufacturer’s
instructions [12]. The BioRad-Avidity assay is based on the
Genetic Systems 1/2+O ELISA [13] (Bio-Rad Laboratories,
Redmond, WA), using diethyl amine as the chaotropic agent with
the following modification: the diethyl amine was diluted in water
and the initial incubation time was decreased to 30 minutes. CD4
cell count data were obtained in the cohort studies.
LAg-Avidity Assay Performance in Clade B Setting
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Samples analyzed using the LAg-Avidity assay alone were
classified as assay positive (below the assay cutoff) or assay negative
(above the assay cutoff); similarly, samples analyzed using MAAs
were classified as MAA positive (meeting the criteria of all
component assays) or MAA negative (failing to meet the criteria of
one or more of the component assays). Samples classified as assay
positive or MAA positive are counted as incident infections in
incidence estimates.
In the first phase of the analysis, we calculated the number of
samples classified as assay positive or MAA positive by duration of
infection (years after HIV seroconversion). For individuals who
had acute or early HIV infection at the time of sample collection
(Fiebig stage I or II [32]), seroconversion was assumed to have
occurred within 28 days after sample collection. For other
individuals, seroconversion was assumed to have occurred
between the last negative and first positive HIV tests. For these
individuals the median number of days between last negative and
first positive HIV tests was 184 days (interquartile range: 168–201
days). We first assessed performance of: (1) the LAg-Avidity assay
alone (assay cutoffs: 0.5, 1.0, 1.5, or 3.0 OD-n), (2) a 3-assay MAA
that included the LAg-Avidity assay (assay cutoff: 1.5 OD-n) with
viral load (assay cutoff: 1,000 copies/mL) and CD4 cell count
(assay cutoff: 200 cells/mm
3), and (3) 2-assay MAAs that included
the LAg-Avidity assay (assay cutoffs of 1.0 or 1.5 OD-n) and viral
load (assay cutoff: 1,000 copies/mL) without CD4 cell count. For
these analyses, duration of infection was classified into time
intervals by midpoint imputation.
The proportion of samples that were classified as assay positive
or MAA positive was also assessed as a function of duration of
infection by fitting logistic regression models with cubic splines
[14]. Seroconversion dates were sampled from uniform distribu-
tions over the potential seroconversion intervals defined above.
The mean window period (i.e., mean duration a person is assay or
MAA positive) and the shadow (a measure of how far back in time
incidence is being estimated [32,33]) were estimated by using
multiple imputation and averaging the results from the fitted
curves [14,33,34]. The mean window period and shadow were not
calculated for an assay or MAA if the probability of a positive
result did not converge to zero (,0.001) by 8 years after
seroconversion. To account for multiple samples from the same
individual, confidence intervals (CIs) were calculated using boot-
strapping, blocking on individuals (so that all samples from the
same individual were included in each bootstrapped sample). The
bootstrap was stratified by cohort study [14,33,34].
The second phase of the analysis further assessed the
performance of the LAg-Avidity assay alone and MAAs that
included other serologic and non-serologic assays to determine
optimal algorithms based on criteria described below. Over 30,000
testing algorithms were considered by analyzing all possible
combinations of the following cutoffs for the component assays:
LAg-Avidity assay: 22 cutoffs ranging from 0.5–3.9 OD-n;
BioRad-Avidity assay: 12 cutoffs ranging from 30–100% (avidity
index); viral load: 10 cutoffs ranging from 400–10,000 copies/mL;
CD4 cell count: 12 cutoffs ranging from 50–1,000 cells/mm
3. The
goal of this analysis was to evaluate different cutoffs for the LAg-
Avidity assay alone, and to identify MAAs with optimal assay
combinations and assay cutoffs [14]. Testing algorithms were
evaluated further if they met the following requirements: (1) the
estimated probability of being classified as assay or MAA positive 8
years after seroconversion was ,0.001 (based on analysis of
samples from the MACS, ALIVE, and HIVNET 001 cohorts), (2)
all 500 samples from the JHHCC (all infected .8 years) were
classified as assay or MAA negative, (3) the shadow was ,250 days
and the upper 95% confidence limit of the shadow was ,1 year.
For each class of testing algorithms that met these requirements,
we identified and deemed optimal the assay or MAA that had the
largest mean window period, as this minimizes the variability in
incidence estimates [33]. We then expanded the search to
.500,000 algorithms that included all combinations of the assays
and cutoffs listed above, along with the BED-CEIA (using 16
cutoffs for the BED-CEIA ranging from 0.4 to 1.8 OD-n).
In the third phase of the analysis, we compared the number of
samples needed in cross-sectional surveys to obtain the same
precision in incidence estimates using two optimized MAAs
(relative sample size, calculated as the ratio of the mean window
periods). We also compared the relative cost of the two MAAs,
optimizing the order of the component assays. For this analysis,
the relative costs of the LAg-Avidity assay, BioRad-Avidity assay,
CD4 cell count, and viral load were considered to be r, r, 2.5r, and
5r, respectively, where r is the unit cost of the LAg-Avidity assay.
For the cost analysis, CD4 cell count was listed first when used in a
MAA, since CD4 cell count must be performed at the time of
sample collection. In addition, costs were adjusted by multiplying
the relative costs by the relative sample sizes that are needed to
account for differences in mean window periods. These analyses
considered only the cost of sample testing.
In the last phase of the analysis, we compared cross-sectional
incidence estimates obtained using the LAg-Avidity assay and
MAAs to longitudinal incidence estimates previously reported for
three cohort studies from the US with varying HIV incidence.
Cross-sectional incidence estimates were calculated for: (1) the
LAg-Avidity assay alone (using assay cutoffs of 1.0 or 1.5 OD-n),
(2) the LAg-Avidity assay with viral load and CD4 cell count (using
assay cutoffs of 1.5 OD-n, 1,000 copies/mL, and 200 cells/mm
3,
respectively), and (3) two optimized MAAs. These analyses were
performed for the following three cohorts: HIVNET 001 (see
above), HPTN 061 (a cohort of black MSM) [30], and HPTN 064
(a cohort of women in high poverty areas at increase risk of HIV
acquisition) [31]. For these analyses, cross-sectional incidence
estimates were calculated as: [(number of samples classified as
assay or MAA positive)6(100)]/[(number of HIV-negative sam-
ples)6(mean window period in years)]. The CIs calculated for
these estimates accounted for uncertainty in the mean window
period [35].
Human subjects
The cohort studies described in this report were conducted
according to the ethical standards set forth by the institutional
review boards of the participating institutions and the Helsinki
Declaration of the World Medical Association; participants
provided written informed consent. The work described in this
report involved analysis of stored samples and data from those
studies. No participants were recruited or followed in the course of
this work. This research was approved by the Institutional Review
Board of the Johns Hopkins University.
Results
Performance of the LAg-Avidity assay used in a single-
assay format
We first calculated the proportion of samples that were classified
as assay positive by duration of infection using the Lag-Avidity
assay alone, using four different assay cutoffs (Table 1). Using the
cutoff of 1.0 OD-n that was originally recommended for this assay
[23], 32% of samples from individuals infected ,6 months were
classified as assay positive, while 3% of samples from individuals
infected .5 years were classified as assay positive. Raising the
LAg-Avidity Assay Performance in Clade B Setting
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manufacturer [24]) increased the percentage of samples from
individuals infected ,6 months that were classified as assay
positive (from 32% to 43%), but also increased the percentage of
samples from individuals infected .5 years who were classified as
assay positive (from 3% to 5%). When the assay cutoff was
increased to 3.0 OD-n, a greater proportion of samples from
individuals infected ,6 months were classified as assay positive
(74%), but a much larger proportion of samples from individuals
infected .5 years were classified as assay positive (15%). When the
assay cutoff was lowered to 0.5 OD-n, the percentage of
individuals infected .5 years classified as assay positive dropped
to 2%; however, at this stringent cutoff, only 13% of samples from
individuals infected ,6 months were classified as MAA positive.
The proportion of individuals classified as assay positive using
the LAg-Avidity assay alone was also analyzed by fitting
probability models with cubic splines (Figure 1A). These proba-
bility models did not approach 0% assay positive by 8 years using
any of the four cutoffs; this indicates that the assay continued to
classify some individuals as assay positive 8 years after serocon-
version. We did not calculate mean window periods or shadows for
the LAg-Avidity assay using any of these assay cutoffs, because of
the persistent classification of samples from individuals with long-
term HIV infection as assay positive.
Performance of the LAg-Avidity assay in MAAs that
included HIV viral load, with or without CD4 cell count
The package insert included with the LAg-Avidity assay
recommends excluding individuals with advanced HIV disease
(CD4 cell count ,200 cells/mm
3), elite controllers, and individ-
uals on antiretroviral therapy. To address this, we evaluated the
performance of the LAg-Avidity assay in a 3-assay MAA that
included viral load and CD4 cell count (Table 2). In contrast to the
LAg-Avidity assay alone, this MAA did not classify any samples
from individuals infected .5 years as MAA positive and had a
shadow ,1 year (158 days). Our analysis indicated that this MAA
had a mean window period of only 85 days, which is lower than
the mean window period of 130 days (95% CI: 118–142) provided
in the current package insert [24].
For comparison, we evaluated the performance of the LAg-
Avidity assay in 2-assay MAAs that included viral load without
CD4 cell count (Table 2). For this analysis, we evaluated two
MAAs that included the LAg-Avidity assay (using an assay cutoff
of 1.0 or 1.5 OD-n) with viral load (assay cutoff: of 1,000 copies/
mL). A viral load cutoff of 1,000 copies/mL was used previously
by the developers of the LAg-Avidity assay to identify individuals
with viral suppression [36]. These 2-assay MAAs classified 2–4%
of the samples from individuals infected for 4–5 years and some
individuals infected .5 years as MAA positive. In contrast to the
LAg-Avidity assay alone (Figure 1), these two MAAs did converge
to 0% MAA positive by 8 years (data not shown). These MAAs
had mean window period of 80 and 134 (using LAg-avidity assay
cutoffs of 1.0 and 1.5, respectively). However, the shadows for
these MAAs were .1 year (446 and 690 days respectively),
indicating that these MAAs were estimating incidence over more
than a year prior to sample collection. Therefore, these MAAs
were not evaluated further.
Table 1. Number of samples classified as assay positive using
the LAg-Avidity assay alone.
Duration of
infection Lag-Avidity assay cutoff
(years) N ,0.5 ,1.0 ,1.5 ,3.0
0.0 to ,0.5 142 18 (13%) 46 (32%) 61 (43%) 105 (74%)
0.5 to ,1.0 167 8 (5%) 17 (10%) 36 (22%) 75 (45%)
1.0 to ,2.0 262 20 (8%) 25 (10%) 35 (13%) 90 (34%)
2.0 to ,3.0 301 21 (7%) 28 (9%) 34 (11%) 69 (23%)
3.0 to ,4.0 440 10 (2%) 17 (4%) 23 (5%) 64 (15%)
4.0 to ,5.0 125 1 (1%) 5 (4%) 11 (9%) 15 (12%)
$5.0 343 7 (2%) 10 (3%) 18 (5%) 51 (15%)
Samples from the MACS, ALIVE, and HIVNET 001 cohorts (N=1,780) were tested
using the LAg-Avidity assay (LAg). Four assay cutoffs were evaluated: 0.5, 1.0,
1.5, and 3.0 optical density units (OD-n); samples were classified as assay
positive if they were below the assay cutoff. The number and percentage of
samples that were assay positive are presented separately for individuals with
different durations of HIV infection (see Methods). N indicates the number of
samples in each group.
doi:10.1371/journal.pone.0082772.t001
Figure 1. Proportion of samples classified as assay positive using the LAg-Avidity assay alone or with HIV viral load, as a function of
the duration of HIV infection. Probability curves were generated by analyzing samples from three cohort studies (see Methods). (A) Probability
curves generated using the LAg-Avidity assay with four different assay cutoffs (0.5, 1.0, 1.5, and 3.0 normalized optical density units [OD-n]). Samples
were classified as assay positive if the LAg-Avidity assay result was below the assay cutoff. (B) Probability curves generated using the MAAs shown in
Figure 2. Samples were classified as MAA positive if results from each of the component assays met the requirements of the MAA.
doi:10.1371/journal.pone.0082772.g001
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The next step in the analysis was to compare the performance of
.30,000 testing algorithms that included the LAg-Avidity assay
alone or in combination with up to three other assays, using a
range of cutoffs for each assay (see Methods). For each class of
testing algorithms that met pre-set requirements (see Methods), we
identified the MAA that had the largest mean window period
(referred to as optimized MAAs). None of the algorithms using the
LAg-Avidity assay alone or the LAg-Avidity assay with viral load
met pre-set performance requirements (see Methods). The
optimized 2-assay MAA included the LAg-Avidity and BioRad-
Avidity assays (MAA #1, Figure 2); this MAA had a mean window
period of 119 days. The optimized 4-assay MAA included the
LAg-Avidity assay, the BioRad-Avidity assay, CD4 cell count, and
viral load (MAA #2, Figure 2); this MAA had a mean window
Table 2. Performance characteristics of MAAs that include the LAg-Avidity assay and HIV viral load, with and without CD4 cell
count.
Duration of infection (years) N LAg ,1.0 VL .1,000 LAg ,1.5 VL .1,000
CD4 .200 LAg ,1.5 VL
.1,000
0.0 to ,0.5 142 32 (23%) 46 (32%) 45 (32%)
0.5 to ,1.0 167 4 (2%) 13 (8%) 13 (8%)
1.0 to ,2.0 262 3 (1%) 3 (1%) 0 (0%)
2.0 to ,3.0 301 4 (1%) 4 (1%) 2 (1%)
3.0 to ,4.0 440 2 (,1%) 4 (1%) 1 (,1%)
4.0 to ,5.0 125 3 (2%) 5 (4%) 1 (1%)
$5.0 343 1 (,1%) 4 (1%) 0 (0%)
Mean Window Period 80 days 134 days 85 days
Shadow 446 days 690 days 158 days
Samples from the MACS, ALIVE, and HIVNET 001 cohorts (N=1,780) were tested using MAAs that included the LAg-Avidity assay and HIV viral load, with and without
CD4 cell count. The cutoffs used for the LAg-Avidity assay (1.0 or 1.5 normalized optical density units [OD-n]) and the cutoff used for CD4 cell count (200 cells/mm
3)a r e
recommended by the assay manufacturer. The cutoff used for HIV viral load (VL, 1,000 copies/mL) was previously suggested for use with the Lag-Avidity assay along
with self-report of antiretroviral treatment [35]. Samples were classified as MAA positive if they met the criteria of each component assay. In the table, CD4 cell count
testing is listed first in the MAA, since that testing must be performed at the time of sample collection. The number and percentage of samples that were MAA positive
are presented separately for individuals with different durations of HIV infection (see Methods). N indicates the number of samples in each group. The mean window
period and shadow for each MAA are shown.
doi:10.1371/journal.pone.0082772.t002
Figure 2. Optimized multi-assay algorithms (MAAs). The figure shows two optimized MAAs that include the LAg-Avidity assay. The assays,
assay cutoffs, window periods, and shadows are shown for each MAA. The 95% confidence intervals for the window periods and shadows are shown
in parentheses. Abbreviations: LAg-Avidity: limiting antigen (LAg) avidity assay; BioRad-Avidity: BioRad-Avidity assay; OD-n: normalized optical
density. The following units are used for the component assays: LAg-Avidity assay: OD-n; BioRad-Avidity assay: percentage (avidity index); CD4 cell
count: cells/mm
3; viral load: copies/mL.
doi:10.1371/journal.pone.0082772.g002
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.30,000 algorithms evaluated. Interestingly, our search did not
identify a 3-assay MAA that was superior to either the optimized
2-assay MAA or the optimized 4-assay MAA (considering mean
window period and relative cost).
Because the target antigens used in the LAg-Avidity assay and
BED-CEIA are similar [12,17], we did not include the BED-CEIA
in our initial analyses. When we expanded the search to include
the BED-CEIA, the best MAA identified (from among .500,000
MAAs evaluated) included the BED-CEIA (assay cutoff 1.6 OD-
n), the BioRad-Avidity assay (assay cutoff 85%), CD4 cell count
(assay cutoff: 200 cells/mm
3), and viral load (assay cutoff: 400
copies/mL); this MAA is identical to MAA #2 (Figure 2), except
that the LAg-Avidity assay is replaced with the BED-CEIA.
Because the 4-assay MAA that includes the BED-CEIA is identical
to the optimized 4-assay MAA described in a previous report [14],
we did not perform any additional analyses with that MAA.
Performance characteristics of the optimized 2-assay and 4-
assay MAAs (MAA #1 and MAA #2, Figure 2) are shown in
Table 3. Probability curves for these MAAs are shown in
Figure 1B. The proportion of samples identified as MAA positive
converged to zero for both MAAs, and none of the 845 samples
from individuals infected .5 years was classified as MAA positive
(Table 3). Because the 2-assay MAA has a shorter mean window
period than the 4-assay MAA (119 days vs. 146 days), larger cross-
sectional surveys would be required to obtain incidence estimates
with the same precision (relative sample size: 123% compared to
MAA #2).
Relative cost of optimized MAAs
We compared the relative cost of sample analysis using the
optimized 2-assay and 4-assay MAAs (Table 3, see Methods).
Relative cost was also adjusted for the mean window period of
each MAA, to account for differences in the sample sizes that
would be needed to obtain incidence estimates with similar
precision. This analysis assumed that testing would be performed
using the assays in the order shown in Figure 2. The cost of the 2-
assay MAA was less than a third of the cost of the 4-assay MAA,
even after adjusting for the shorter mean window period.
Of note, one of the MAAs evaluated in the initial search of over
.30,000 algorithms was the 3-assay MAA described above that
included the LAg-Avidity assay (cutoff ,1.5 OD-n), viral load
(cutoff .1,000 copies/mL) and CD4 cell count (cutoff .200 cells/
mm
3, Table 2) [24]. The implication of the lower mean window
period (85 vs. 130 days) is that an incidence survey would have to
be 72% larger using this MAA than one using the optimized 4-
assay MAA (mean window period 146 days), and 40% larger than
one using the optimized 2-assay MAA (mean window period 119
days). Furthermore, the adjusted relative cost of this 3-assay MAA
(using a window period of 85 days) was greater than the costs of
both the optimized 2 and 4-assay MAAs, which makes it
undesirable. Even if the manufacturer’s recommended mean
window period of 130 days were used to adjust the relative cost of
the 3-assay MAA, it would still be more costly than both of the
optimized MAAs (adjusted relative cost: 342% compared to the
optimized 2-assay MAA, 106% compared to the optimized 4-assay
MAA).
Comparison of incidence estimates obtained using
optimized MAAs to those obtained from cohort follow-
up
As a final step in our analysis, we used the LAg-Avidity assay
alone and selected MAAs to generate cross-sectional incidence
estimates for three cohorts: HPTN 064, HIVNET 001, and
HPTN 061 (see Methods, Table 4). These incidence estimates
were compared to longitudinal incidence based on cohort follow-
up [30,31,37]. When the LAg-Avidity assay was used alone with a
cutoff of 1.0 or 1.5 OD-n (cutoffs recommended by the
manufacturer), the 95% CIs of the incidence estimates did not
cover the longitudinal incidence point estimates for one of the
three cohorts (HPTN 061). In contrast, the 95% CIs for all three of
the MAAs evaluated covered the longitudinal incidence point
estimates for all three cohorts. In addition, the incidence estimates
obtained using the MAAs were much closer to the longitudinal
estimates than the incidence estimates obtained using the LAg-
Avidity assay alone for the two cohorts that included individuals
with long-term infection (i.e., individuals who were HIV infected
at enrollment, HPTN 064 and HPTN 061, % difference, Table 4).
The optimized 4-assay MAA provided incidence estimates that
were closest to the longitudinal incidence estimates for all three
cohorts (cross-sectional vs. longitudinal estimates: HPTN 064:
Table 3. Performance characteristics of optimized MAAs that
include the LAg-Avidity assay.
MAA #1 MAA #2
– CD4 .50
Duration of
infection BioRad ,40 BioRad ,85
(years) N LAg ,2.8 LAg ,2.9
–V L .400
0.0 to ,0.5 142 57 (40%) 76 (53%)
0.5 to ,1.0 167 8 (5%) 24 (14%)
1.0 to ,2.0 262 6 (2%) 4 (2%)
2.0 to ,3.0 301 4 (1%) 2 (1%)
3.0 to ,4.0 440 4 (1%) 3 (1%)
4.0 to ,5.0 125 2 (2%) 1 (1%)
5.0 to ,8.0 333 0 (0%) 0 (0%)
$8.0 512 0 (0%) 0 (0%)
Mean Window Period 119 (94, 144) 146 (122, 170)
Shadow 247 (160, 339) 180 (144, 235)
Relative sample size 123% 100%
Relative cost 25% 100%
Adjusted relative cost 31% 100%
Samples from the MACS, ALIVE, and HIVNET 001 cohorts (N=1,782) and
samples from the JHHCC cohort (N=500) were tested using MAAs that
included the LAg-Avidity assay (MAA #1 and MAA #2, Figure 2). The following
units were used for the component assays: LAg-Avidity assay, normalized
optical density units (OD-n); BioRad-Avidity assay, percentage (avidity index);
viral load, copies/mL; CD4 cell count, cells/mm
3. Samples were classified as MAA
positive if they met the criteria for all of the assays in the MAA (Figure 2). The
number and percentage of samples that were MAA positive are presented
separately for individuals with different durations of HIV infection (see
Methods). N indicates the number of samples in each group. The following
additional performance measures are shown: mean window period, shadow,
relative sample size needed for cross-sectional surveys (with MAA #2a sa
reference), relative cost, and relative cost adjusted for the mean window period
(with MAA #2 as a reference) (see Methods). The cost analyses assumed that
assays would be performed in the order shown.
doi:10.1371/journal.pone.0082772.t003
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Discussion
This report includes a comprehensive evaluation of the
performance of the LAg-Avidity assay alone and MAAs that
include the LAg-Avidity assay. When used in a single-assay format,
the LAg-Avidity assay classified a smaller proportion of samples
from individuals with long-term infection as assay positive than the
BED-CEIA alone (based on comparison to results previously
obtained for the BED-CEIA using the same sample sets [14]).
However, the LAg-Avidity assay still classified some individuals
with long-term infection as assay positive and failed to provide
accurate HIV incidence estimates in cohorts that included
individuals with long-term infections (HPTN 064 and HPTN
061). Some individuals who were infected .5 years were also
classified as MAA positive when the LAg-Avidity assay was used in
2-assay MAAs that also included viral load. Furthermore, MAAs
that included only the LAg-Avidity assay and viral load had
shadows that were .1 year, indicating that they were estimating
incidence more than a year prior to sample collection.
Table 4. HIV incidence estimates for three clinical cohorts in the United States.
Method used to estimate
incidence Window period HPTN 064
a HIVNET 001 HPTN 061
b
Longitudinal – Follow-up period (months) 0–12 12–18 0–12
# seroconverters 4 24 28
Person-years follow-up 1,639 2,304 926
Observed incidence 0.24% (0.07, 0.62) 1.04% (0.70, 1.55) 3.02% (2.01, 4.37)
Cross-sectional – Visits analyzed (months) 6–12 18 12
# HIV positive
c 33 90 246
# HIV negative 1,947 4,175 872
Study visit (months) (12) (18) (12)
# tested 33 79 246
LAg-Avidity ,1.0 141 days
d # assay positive 4 12 20
Incidence estimate 0.53% (0.07, 1.39) 0.85% (0.43, 1.52) 5.94% (3.56, 9.45)
% difference 121% 218% 97%
LAg-Avidity ,1.5 130 days
d # assay positive 4 15 29
Incidence estimate 0.58% (0.16, 1.49) 1.15% (0.64, 1.92) 9.34% (6.20, 13.59)
% difference 142% 11% 209%
LAg-Avidity ,1.5 + 130 days
d # MAA positive 2 8 8
viral load .1,000 + Incidence estimate 0.29% (0.03, 1.05) 0.61% (0.26, 1.22) 2.58% (1.11, 5.12)
CD4 .200 % difference 21% 241% 215%
MAA #1 119 days
e # MAA positive 2 11 13
Incidence estimate 0.32% (0.04, 1.17) 0.92% (0.45, 1.73) 4.57% (2.37, 8.24)
% difference 33% 212% 51%
MAA #2 146 days
e # MAA positive 2 16 12
Incidence estimate 0.26% (0.03, 0.95) 1.09% (0.60, 1.84) 3.44% (1.75, 6.20)
% difference 8% 5% 14%
The table shows cross-sectional and longitudinal incidence estimates for three clinical cohorts (see Methods); 95% confidence intervals are shown in parentheses.
Longitudinal incidence estimates were calculated as the number of seroconversion events divided by the number of person-years of follow-up; these estimates were
reported previously [26,29–30]. The % difference is defined as: 1006(the absolute value of the difference between the longitudinal incidence estimate and the cross-
sectional incidence estimate) divided by the longitudinal incidence estimate. Cross-sectional incidence estimates were obtained using five testing approaches (the
original LAg-Avidity protocol, the revised LA-Avidity protocol, the 3-assay MAA in Table 2, and MAA #1 and MAA #2, described in Figure 2). The following units were
used for the component assays: LAg-Avidity assay: normalized optical density units (OD-n); BioRad-Avidity assay: percentage (avidity index); viral load: copies/mL; CD4
cell count: cells/mm
3.
aIn HPTN 061, some study participants who contributed to the longitudinal incidence estimate did not complete the 12-month study visit or did not have a sample
stored at that visit and were not included in the cross-sectional incidence estimates.
bIn HPTN 064, the primary study outcome was overall HIV incidence, measured as a composite incidence estimate that took into account cross-sectional incidence at
enrollment (estimated using a MAA), acute infections at enrollment, and observed incidence during longitudinal follow-up (based on HIV seroconversion). The overall
HIV incidence in the HPTN 064 study was 0.32% (95% CI: 0.14–0.74%) [30]. In that study, cross-sectional incidence was assessed using a MAA that included the BED-CEIA,
the BioRad-Avidity assay, CD4 cell count, and HIV viral load [43].
cFor HPTN 064: A total of 38 women were identified with HIV-infection in the HPTN 064 study. The 33 HIV-positive women included in the cross-sectional incidence
assessment at 6–12 months included 28 women who were seropositive at study enrollment, one woman who had acute HIV infection at enrollment, and four women
who acquired HIV infection during the study. For HIVNET 001: All participants included in the cross-sectional incidence assessment were HIV-uninfected at study
enrollment. For HPTN 061: The 246 men included in the cross-sectional incidence assessment at 12 months included 218 men who were seropositive at study
enrollment, three men who had acute HIV infection at enrollment, and 25 men who acquired HIV infection during the study.
dIncidence estimates using these testing approaches were calculated using window periods recommended by the manufacturer of the LAg-assay.
eIncidence estimates using the two optimized MAAs (MAA #1 and MAA #2) were calculated using window periods determined in this report (Table 3).
doi:10.1371/journal.pone.0082772.t004
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different testing algorithms that included the LAg-Avidity assay,
we identified an optimized 2-assay MAA and an optimized 4-assay
MAA. Both of these MAAs include the LAg-Avidity assay and the
BioRad-Avidity assay; the 4-assay MAA also includes CD4 cell
count and viral load. Both of the optimized MAAs classified all
845 samples from individuals infected .5 years as MAA negative.
Furthermore, both of the optimized MAAs provided cross-
sectional incidence estimates that were similar to those obtained
by longitudinal follow-up for three cohorts in the US with varying
HIV incidence. The 4-assay MAA was the top-performing MAA
among .30,000 MAAs that did not include the BED-CEIA; this
MAA provided incidence estimates that were nearly identical to
those obtained by cohort follow-up. Of note, the performance of
the optimized 4-assay MAA described in this report was very
similar to that of an optimized 4-assay MAA which was the best
MAA in the expanded search of .500,000 algorithms; that MAA
included the BED-CEIA rather than the LAg-Avidity assay
(described previously [14,16]). These two MAAs use the same
cutoffs for the BioRad-Avidity assay, CD4 cell count, and viral
load.
Acceptable incidence estimates were also obtained using a 3-
assay MAA that included the LAg-Avidity assay, CD4 cell count,
and viral load. The cutoffs used for the LAg-Avidity assay (1.5
OD-n) and CD4 cell count (200 cells/mm
3) in this MAA are
recommended by the manufacturer [24], the cutoff used for viral
load (1,000 copies/mL) was used by the developers of the LAg-
Avidity assay in a previous study (in conjunction with self-reported
use of antiretroviral therapy (ART) [36]. We did not include self-
report of ART in our algorithms; recent reports indicate that self-
report of ART use is often unreliable [38–40]. This 3-assay MAA
did not classify any of samples from individuals infected .5 years
as MAA positive and had a shadow ,1 year. However, our
analysis indicated that this MAA had a mean window period of
only 85 days, which is shorter than the mean window period of
130 days (95% CI: 118–142) provided in the current package
insert [24] and is shorter than the mean window periods of the
optimized 2-assay and 4-assay MAAs (119 and 146 days,
respectively). The implication of the lower mean window period
is that a cross sectional survey to measure incidence would have to
be larger using the 3-assay MAA than one using either the
optimized 2-assay or the optimized 4-assay MAA. Furthermore,
the adjusted relative cost for sample testing using this 3-assay MAA
was greater than the cost for sample testing using the optimized 4-
assay MAA, which makes it difficult to justify its use.
We recognize that the confidence intervals for incidence
obtained using the MAAs (which incorporate uncertainty in the
mean window period) are larger than those obtained by
longitudinal follow-up of cohorts. Additional studies that improve
the precision of the mean window period would reduce the width
of these confidence intervals. The width of the confidence intervals
could also be reduced with larger cross-sectional surveys.
Furthermore, even with larger cross-sectional surveys, it may be
less expensive to estimate incidence using a MAA than a cohort
study because no longitudinal follow-up is required.
Our identification of an optimized 2-assay MAA that does not
require CD4 cell count or HIV viral load has major implications
for global HIV surveillance. The optimized 2-assay MAA
identified in this report, which includes the LAg-Avidity and
BioRad-Avidity assays without CD4 or viral load, has lower testing
costs than the optimized 4-assay MAA, even after accounting for
the larger sample sizes that would be needed with the 2-assay
MAA because of its shorter mean window period. Note that this
cost comparison only included costs for laboratory testing; costs
associated with obtaining samples for analysis were not included in
this analysis. Because the 2-assay MAA does not require CD4 cell
count data, it can be performed entirely using stored plasma or
serum samples, which would be an advantage in some studies. We
previously described an optimized 3-assay MAA that included the
BED-CEIA, the BioRad-Avidity assay, and viral load (without
CD4 cell count) [14]; an advantage of the 2-assay MAA described
in this report over the 3-assay MAA described in the previous
report [14] is that the 2-assay MAA also does not require viral load
testing. Furthermore, recent data suggests that both the LAg-
Avidity and BioRad-Avidity assays can be performed using dried
blood spots [18,41]. This could significantly reduce the complexity
and cost of sample acquisition, shipping and storage in incidence
surveys.
The samples used in this report were obtained from diverse
cohorts that included men and women of different ethnicities and
ages; and individuals infected through heterosexual, homosexual
and parenteral routes. All of these samples were from the US
where the most prevalent HIV-1 subtype is B. Serologic assays
developed for cross-sectional incidence estimation have been
shown to perform differently depending on the infecting subtype
[7,42,43]. Therefore, additional studies are needed to evaluate the
performance of the LAg-Avidity assay (alone and in MAAs) in
populations where other HIV-1 subtypes are prevalent.
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